“We're really moving into not just these annual meetings, but we're going to have some programs throughout the year that will be targeted towards…really important, impactful research that comes out,” says Michael S. Cookson, MD, MMHC, FACS.
In this video, the Society of Urologic Oncology’s (SUO) Past President Michael S. Cookson, MD, MMHC, FACS, discusses his impressions of the 2021 SUO Annual Meeting and what educational initiatives are taking place in 2022 leading up to next year’s meeting. Cookson is a professor and the Donald D. Albers endowed chair in urology at the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.